Pharsight

Drugs that contain Ivacaftor; Ivacaftor, Tezacaftor

1. Symdeko (copackaged) patents expiration

SYMDEKO (COPACKAGED)'s oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(2 years from now)

US11639347 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(2 years from now)

US10239867 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(2 years from now)

US7645789 VERTEX PHARMS INC Indole derivatives as CFTR modulators
May, 2027

(2 years from now)

US8623905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(2 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(2 years from now)

US7776905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(1 year, 25 days from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jul, 2026

(2 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(2 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(2 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(2 years from now)

US9974781 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(2 years from now)

US10022352 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(2 years from now)

US8598181 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(2 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Aug, 2027

(3 years from now)

US8415387 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Nov, 2027

(3 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(5 years from now)

US11564916 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(5 years from now)

US10081621 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
Mar, 2031

(6 years from now)

US11578062 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
Mar, 2031

(6 years from now)

US10058546 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
Jul, 2033

(9 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
Jul, 2033

(9 years from now)

US10206877 VERTEX PHARMS INC Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
Apr, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-173) Feb 12, 2025
Orphan Drug Exclusivity(ODE-247) Jun 21, 2026
Orphan Drug Exclusivity(ODE-335) Dec 21, 2027
New Chemical Entity Exclusivity(NCE) Feb 12, 2023
New Patient Population(NPP) Jun 21, 2022

NCE-1 date: 12 February, 2022

Market Authorisation Date: 21 June, 2019

Treatment: Tezacaftor and ivacaftor for the treatment of patients with a mild to moderate clinical phenotype of cystic fibrosis having at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor b...

Dosage: TABLET;ORAL

More Information on Dosage

SYMDEKO (COPACKAGED) family patents

Family Patents